α₄β₇ integrin inhibitors: a patent review

SARS‐COV‐2 and infectivity: Possible increase in infectivity associated to integrin motif expression

“…Of additional interest is the use of molecules able to interfere with cytokines production, 9 as these biomolecules are responsible for the modulation of integrin expression. [10][11][12][13][14][15] Our conclusion is that further investigation into any possible links between integrin-binding peptides and their correlation with coronavirus infectivity and diffusion are needed, especially considering that their possible inhibition could be a potential therapeutic target for the SARS-COV-2 infection.…”

Mucosal integrin α4β7 blockade fails to reduce the seeding and size of viral reservoirs in SIV‐infected rhesus macaques

“…In addition to anti-α 4 β 7 Ab, the small molecule TR-14035 can block both α 4 β 1 and α 4 β 7 integrins, and its therapeutic potential is being tested in inflammatory diseases. [51][52][53] To evaluate the potential efficacy of integrin blockade , SIVinfected animals were treated by intravenous infusion of anti-rhesus α 4 β 7 mAb at −7 and 21 post-SIV inoculation or orally administered TR-14035 daily for 2-weeks after SIV inoculation (Figure 1A). Consistent with previous reports, 25 α 4 β 7 mAb levels in plasma peaked after one week of antibody infusion, and gradually declined afterward (Figure 1B).…”

Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives

“…In addition, α 4 β 1 integrin contributes to the infiltration of T cells to the inflamed intestinal tissue (Zundler et al, 2017b). Natalizumab, targeting α 4 integrin subunit, has been approved for the treatment of MS and for CD, although due to fatal adverse reactions, its use is very limited for CD (Li et al, 2018; Nelson et al, 2018). Recently it has been observed that vedolizumab did not cause a decrement in homing of T cells into the gut, which instead was achieved by blocking α 4 β 1 .…”